BioNTech has named Guido Oelkers, formerly CEO of Swedish biopharma Sobi, as its next CEO, continuing the company’s shift from COVID-era mRNA manufacturing toward an oncology-focused platform. Oelkers will replace co-founder Ugur Sahin, with Oelkers scheduled to start no later than Feb. 1, 2027. In parallel, Sahin is preparing to lead a new mRNA startup, as BioNTech previously announced management changes related to the new venture. The move puts Sobi’s leadership experience into a company executing post-pandemic strategy changes, including organizational restructuring and pipeline prioritization in oncology. For investors, the appointment signals continuity in BioNTech’s international expansion plans while formalizing leadership as the company navigates its oncology transition and mRNA ecosystem split.